SAUDI-FUND-DEVELOPMENT
2.9.2024 20:55:35 CEST | Business Wire | Press release
The Saudi Fund for Development (SFD) celebrated its 50th anniversary in Riyadh today, under the theme "50 Years of Global Impact." The event brought together key development partners to reflect on the SFD’s significant contributions to sustainable development worldwide. Over the past five decades, the SFD has allocated over $20 billion, financing more than 800 development projects and programs in vital sectors, including social infrastructure (education, healthcare, water and sewage, and housing and urban development), communication and transportation (roads, railways, airports and seaports), energy, agriculture, mining and industry, and others.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240902588222/en/
Saudi Fund for Development Celebrates 50 Years of Global Impact with Over $20 Billion in Development Contributions (Photo: AETOSWire)
Since its inception in 1974, the SFD has been the international development arm of the Kingdom of Saudi Arabia and has provided critical support to over 100 developing nations around the world. With a strong focus on supporting countries to achieve the Sustainable Development Goals (SDGs), the SFD has played a pivotal role in driving sustainable development in Least Developed Countries (LDCs) and Small Island Developing States (SIDS).
During the event, SFD Chairman H.E. Ahmed Al-Khateeb emphasized the importance of collaboration in driving global development. He highlighted that SFD's success is deeply rooted in its partnerships, with 27 development projects and programs in 23 developing countries in 2023 co-financed with other funders. He also underscored the need to forge new partnerships and strengthen existing ones to create a world where every individual has the opportunity to reach their full potential.
Reflecting on this significant milestone, the SFD CEO , Mr. Sultan bin Abdulrahman Al-Marshad, stated: “As we celebrate five decades of impactful work, we are committed, now more than ever, to supporting developing countries on their journey to economic self-reliance and resilience. Our goal is to ensure that all children can go to school, that education is not a privilege but something every child should have access to, and that families have access to healthcare and basic vital services. Equally, we focus on critical infrastructure development, like building roads and enhancing airports and sea ports, so that countries can thrive and engage in economic activities and trade. This work is not just about financing; it’s about tangibly improving lives, creating opportunities, empowering communities, and building a more prosperous future.”
On the sidelines of the 50th Anniversary Gala, the SFD and the Asian Development Bank (ADB) signed a new $25 million agreement to co-finance a renewable energy development project in the Solomon Islands. This marks the first project for SFD in the Solomon Islands. The primary aim of the project is to develop renewable energy infrastructure, reduce dependency on fossil fuels, and promote sustainable development in the region.
This agreement builds on SFD’50 years of transformative impact through development projects that have spanned Africa, Asia and the Pacific, Latin America and the Caribbean, and Eastern Europe.
This includes key projects such as the Metolong Dam in Lesotho, which received $25 million in funding and now provides potable water to 280,000 people, enhancing water security and public hygiene and health in the region. This is just one of the 433 projects across Africa, with a total funding of $11.5 billion, which focuses on critical areas such as infrastructure and water security.
In Asia, the SFD has funded 271 projects with a total funding of $7.8 billion. One notable example is the SFD’s contribution to the Mohmand Dam Hydropower Project in Pakistan, which has an overall project cost of $240 million. The projects contributes to the country’s energy security and flood resilience by generating 800 megawatts of renewable energy and storing 1.6 million cubic meters of water.
In Latin America and the Caribbean, the SFD has financed 21 projects, totaling $951 million USD. This includes rehabilitating the Water and Sewage System in Havana, Cuba, where the SFD has allocated $35 million to enhance public infrastructure. Another significant initiative is the rebuilding of St. Jude Hospital in Saint Lucia, supported by $75 million funding, which will contribute to providing high-quality health services to citizens in a modern and sophisticated facility and providing sufficient medical supplies and equipment to support the effective operation of the hospital.
In Eastern Europe, the SFD has contributed to 14 projects with a total investment of $303 million. A key initiative is the construction of the Tirana-Elbasan-Chokos-Chalf-Ploce Road, where the SFD provided $73.8 million to rebuild essential roads and bridges, thereby boosting regional economic activities.
During the celebration, esteemed speakers shared insights on the SFD’s pivotal role in global development, and in championing critical partnerships and collective action and response. Keynote speakers included:
- HRH Prince Turki bin Faisal Al Saud, Founder and Trustee of the King Faisal Foundation
- H.E. Ahmed bin Aqeel Al-Khateeb, Chairman of the Board of Directors of the SFD
- H.E. Akinwumi Adesina, President of the African Development Bank Group
- H.E. Muhammad Al Jasser, Chairman of the Islamic Development Bank
These global development leaders emphasized the SFD’s commitment to fostering sustainable growth in countries and communities with the most pressing developmental needs.
The gala was attended by more than 500 people, including ministers, heads of regional and international organizations, ambassadors, representatives of the United and other distinguished guests.
As the SFD looks to the future, it reaffirms its mission and pledge to drive international development efforts, on behalf of the Kingdom of Saudi Arabia, and to contribute to global stability, social progress, and economic prosperity for future generations.
Note to editors
- For additional information, please reach out to us at media@sfd.gov.sa
- Access the media kit, including collateral from the anniversary, via the following link: media kit
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240902588222/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
